NHS England has said it will start offering flu and COVID-19 vaccinations to people from 11th September, as concern rises about a new coronavirus variant that is spreading
Just a few months after suggesting it may not survive to the end of 2023, Novavax has posted improved finances and a second-quarter profit, as it readies the launch of an
Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a
At the upcoming World Without Disease Summit in London, many speakers will focus on specific treatments, therapies, and programmes that exemplify disease screening, prevention, and interception.
BlueDot hit the headlines in the early stages of the pandemic for using its artificial intelligence platform to predict the outbreak and send out an alert before national
Moderna’s aspiration to become a player in the seasonal influenza vaccine market has hit a hurdle – likely a delay rather than anything more serious – but its stock has st